Rybrevant Plus Lazcluze Associated with Survival Improvement in NSCLC

September 9, 2025
Alex Biese
Alex Biese

A nationally-published, award-winning journalist, Alex Biese joined the CURE team as an assistant managing editor in April 2023. Prior to that, Alex's work was published in outlets including the Chicago Sun-Times, MTV.com, USA TODAY and the Press of Atlantic City. Alex is a member of NLGJA: The Association of LGBTQ+ Journalists, and also performs at the Jersey Shore with the acoustic jam band Somewhat Relative.

For some with previously untreated locally advanced or metastatic non-small cell lung cancer Rybrevant plus Lazcluze improved overall survival.

Among patients with previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or L858R substitution mutations, treatment with Rybrevant (amivantamab) plus Lazcluze (lazertinib) was found to result in a statistically significant and clinically meaningful improvement in overall survival versus treatment with Tagrisso (osimertinib) monotherapy, study results have shown.

Results from the phase 3 MARIPOSA study were published in The New England Journal of Medicine and announced in a news release from Janssen-Cilag International NV, a Johnson & Johnson company.

At a median follow-up time of 37.8 months, the treatment combination of Rybrevant and Lazcluze was associated with a 25% lower risk of death than treatment with Tagrisso. The news release noted that the median overall survival time for the combination is expected to exceed four years versus the median overall survival time of 36.7 months observed with Tagrisso monotherapy.

Glossary

Overall survival: the time a patient lives, regardless of disease status.

Progression-free survival: the time a patient lives without their disease spreading or worsening.

Paronychia: skin infection around the nail.

“This is a turning point in how we treat EGFR-mutated lung cancer,” said Dr. James Chih-Hsin Yang of the Department of Medical Oncology at the National Taiwan University Cancer Center in Taipei, Taiwanin the news release. “We’re now seeing the potential for patients to live significantly longer than we thought possible. Starting with [Rybrevant] plus [Lazcluze] may prevent common types of resistance and reserves chemotherapy for later lines of therapy, which can help achieve better outcomes.”

Yang was the lead author of the MARIPOSA study.

“These published data further reinforce the potential of the chemotherapy-free, dual-targeted [Rybrevant] plus [Lazcluze] regimen to deliver meaningful, long-term clinical outcomes and experiences for patients and their families versus the current standard of care,” said Henar Hevia, senior director of and head of EMEA Therapy Area for oncology at Johnson & Johnson Innovative Medicine.

Among patients who received the treatment combination, the median time to subsequent therapy was 30.3 months versus 24 months with Tagrisso. The combination was also associated with improved progression-free survival after subsequent therapy, with times of 42.9 months versus 32.8 months in the Rybrevant and Tagrisso treatment groups, respectively.

“With these results, we have the potential to change the trajectory of this disease,” said Dr. Joshua Bauml, vice president and disease area leader of lung cancer at Johnson & Johnson Innovative Medicine. “Unmet needs remain high for people living with EGFR-mutated lung cancer. Now, we’re delivering survival outcomes that have the ability to redefine what first-line treatment can achieve.”

The combination’s safety profile was reportedly consistent with the primary analysis, with the most common treatment-related side effects of any grade being paronychia (69%), infusion-related reaction (65%) and rash (64%). The most common grade 3 (severe) or worse side effects were rash (17%), paronychia (12%), dermatitis acneiform (9%), pulmonary embolism (9%) and alanine transaminase increase (7%).

Overall survival findings from MARIPOSA were previously shared earlier this year in a presentation at the 2025 European Lung Cancer Congress, as well as published in a news release from Johnson & Johnson.

“Rybrevant plus Lazcluze helps patients live longer, and the benefit keeps growing over time,” trial investigator, Dr. Nicolas Girard, said in a news release issued at the time. “We see the gap between the survival curves continue to widen, which is exactly what we want to see in lung cancer treatment to improve outcomes for patients. These results reinforce that we are entering a new era for EGFR-mutated non-small cell lung cancer; with this evidence in hand, we need to ensure every patient gets the most effective treatment in the first line for the best possible chance at longer survival.”

Girard, who also presented these data at the meeting, is the head of Medical Oncology at the Institut Curie and a professor of Thoracic Oncology and Respiratory Medicine at the Paris-Saclay University, in France.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Reference

  1. “Data published in The New England Journal of Medicine demonstrate RYBREVANT®(amivantamab) plus LAZCLUZE® (lazertinib) could re-set survival expectations in first-line EGFR-mutated advanced lung cancer,” news release, Sept.7, 2025; https://www.globenewswire.com/news-release/2025/09/07/3145711/0/en/Data-published-in-The-New-England-Journal-of-Medicine-demonstrate-RYBREVANT-amivantamab-plus-LAZCLUZE-lazertinib-could-re-set-survival-expectations-in-first-line-EGFR-mutated-advan.html
  2. “First-line Rybrevant Combo Extends Survival in Advanced Lung Cancer,” CURE, March 31, 2025; https://www.curetoday.com/view/first-line-rybrevant-combo-extends-survival-in-advanced-lung-cancer

Related Content:

Lung Cancer
Zidesamtinib Elicits Responses in ROS1-Positive NSCLC
What Patients With Lung Cancer Need to Know About KRAS G12C Mutations
Ivonescimab Plus Chemo Delays NSCLC Progression